Axovant Sciences Ltd (NASDAQ:AXON) – Stock analysts at Oppenheimer raised their FY2018 earnings estimates for shares of Axovant Sciences in a report issued on Tuesday. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will post earnings of ($2.30) per share for the year, up from their previous forecast of ($2.34). Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Axovant Sciences’ Q4 2018 earnings at ($0.47) EPS, FY2019 earnings at ($1.59) EPS, FY2020 earnings at ($1.28) EPS, FY2021 earnings at ($1.04) EPS and FY2022 earnings at ($0.57) EPS.
A number of other research firms also recently commented on AXON. HC Wainwright restated a “buy” rating on shares of Axovant Sciences in a report on Thursday, October 19th. Jefferies Group downgraded Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target for the company. in a report on Thursday, December 21st. Cowen downgraded Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Friday, January 12th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Wednesday, January 31st. Finally, ValuEngine downgraded Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.61.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Axovant Sciences by 99.8% during the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after purchasing an additional 1,454,454 shares during the last quarter. OxFORD Asset Management LLP lifted its position in shares of Axovant Sciences by 842.1% during the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Eagle Asset Management Inc. bought a new position in shares of Axovant Sciences during the third quarter worth about $4,471,000. Deutsche Bank AG lifted its position in shares of Axovant Sciences by 7.0% during the fourth quarter. Deutsche Bank AG now owns 548,728 shares of the biotechnology company’s stock worth $2,891,000 after purchasing an additional 35,878 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Axovant Sciences by 52.8% during the second quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock worth $12,682,000 after purchasing an additional 188,945 shares during the last quarter. 96.82% of the stock is owned by institutional investors.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.